Epizyme
- Revenue$15.8 MFY, 2020
- Market Capitalization$54.1 M2022-05-13
OverviewSuggest Edit
Epizyme is a clinical stage biopharmaceutical company creating epigenetic therapeutics for patients with cancer. The Company is focused on creating medicines that are targeted at specific causes of diseases, that are orally administered, tolerable, easy to take, and that are based on a deep understanding of the patients that will benefit from them.
Based on clinical proof of concept in treating multiple forms of cancer, Epizyme's lead product candidate, tazemetostat, is being developed for hematologic malignancies and genetically defined solid tumors. The Company is also advancing novel compounds directed against a broad range of disease targets.
| Type | Public | |
| Founded | 2007 | |
| HQ | Cambridge, MA, US | Map |
| Website | epizyme.com | |
| Employee Ratings |
Recent NewsAll News
- HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China
- Thinking about buying stock in Epizyme, AMC Entertainment, Evofem Biosciences, Nokia, or Arcutis Biotherapeutics?
- SVB Leerink upgrades Epizyme, citing sales potential for lymphoma drug
- Epizyme (EPZM) Tazemetostat Interim Phase 2 Data in Follicular Lymphoma - Slideshow
Key People/Management at Epizyme
David M Mott
Chairman
Grant Bogle
President, Chief Executive Officer
Matthew Ros
Executive Vice President, Chief Strategy and Business Officer
Joseph Beaulieu
Senior Vice President, Head of Finance
John Weidenbruch
Senior Vice President, General Counsel
Jeffery Kutok
Chief Scientific Officer
Epizyme Office Locations
Epizyme has an office in Cambridge
Cambridge, MA, US (HQ)
400 Technology Square, 400 Technology Square
Epizyme Financials and Metrics
Epizyme Revenue
Epizyme's revenue was reported to be $15.76 m in FY, 2020
| USD | |
|---|---|
Revenue (Q1, 2021) | 7.6m |
Gross profit (Q1, 2021) | 4.8m |
Gross profit margin (Q1, 2021), % | 62.6% |
Net income (Q1, 2021) | (70.3m) |
EBIT (Q1, 2021) | (64.3m) |
Market capitalization (13-May-2022) | 54.1m |
Closing stock price (13-May-2022) | 0.5 |
Cash (31-Mar-2021) | 73.7m |
EV | 215.2m |
Epizyme's current market capitalization is $54.1 m.
Annual
Quarterly
| USD | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 12.0m | 7.9m | 5.9m | 5.7m | 1.4m | 2.5m | 3.6m | 7.6m | ||||||||||||||||
Cost of goods sold | 614.0k | 1.0m | 1.6m | 2.9m | ||||||||||||||||||||
Gross profit | 740.0k | 1.4m | 2.0m | 4.8m | ||||||||||||||||||||
Gross profit Margin, % | 55% | 59% | 55% | 63% |
Annual
Quarterly
| USD | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 148.7m | 139.6m | 237.1m | 229.9m | 211.7m | 244.5m | 236.7m | 229.9m | 312.7m | 89.5m | 66.0m | 64.4m | 88.5m | 219.8m | 130.3m | 67.9m | 66.3m | 144.3m | 45.9m | 93.5m | 179.3m | 117.2m | 93.4m | 73.7m |
Accounts Receivable | 7.8m | 2.2m | 8.2m | 2.2m | 2.1m | 365.0k | 723.0k | 177.0k | 176.0k | 60.0k | 6.2m | 8.0k | 25.0k | 25.0k | 24.0k | 12.3m | 13.0m | 13.3m | 12.0m | 1.6m | 1.7m | 4.6m | 9.8m | |
Prepaid Expenses | 2.0m | 2.1m | 2.1m | 2.7m | 3.3m | 2.5m | 2.0m | 2.5m | 5.5m | 7.9m | 5.5m | 8.8m | 8.6m | 10.0m | 8.9m | 8.5m | 7.0m | 15.2m | 14.1m | 16.1m | 22.6m | 21.0m | 18.5m | 16.9m |
Inventories | 1.7m | 9.9m | 8.2m | 14.8m |
Annual
Quarterly
| USD | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (9.7m) | (19.4m) | (6.9m) | (20.3m) | (40.0m) | (61.3m) | (87.1m) | (110.1m) | (22.9m) | (50.9m) | (75.2m) | (32.5m) | (60.5m) | (98.1m) | (34.1m) | (63.2m) | (100.7m) | (29.3m) | (77.8m) | (113.9m) | (50.9m) | (109.4m) | (165.5m) | (70.3m) |
Depreciation and Amortization | 363.0k | 534.0k | 169.0k | 362.0k | 548.0k | 260.0k | 653.0k | 1.1m | 389.0k | 791.0k | 1.2m | 411.0k | 824.0k | 1.2m | 361.0k | 582.0k | 804.0k | 207.0k | 416.0k | 626.0k | 512.0k | 1.4m | 2.7m | 1.3m |
Inventories | (1.7m) | (9.9m) | (8.2m) | (4.4m) | ||||||||||||||||||||
Accounts Payable | 290.0k | 364.0k | (1.3m) | (142.0k) | 1.1m | (3.2m) | (5.2m) | (5.3m) | (2.4m) | (980.0k) | (1.3m) | 1.9m | 4.6m | 366.0k | 226.0k | 4.0m | (701.0k) | 3.2m | 2.1m | 573.0k | (2.7m) | (4.2m) | (1.3m) | (4.8m) |
| USD | Q2, 2013 |
|---|---|
Financial Leverage | 1.7 x |
Epizyme Cybersecurity Score
Epizyme Environment, Social & Governance (ESG) Ratings
Epizyme Online and Social Media Presence
2.9k Twitter followers
Epizyme has 2.9k Twitter Followers. The number of followers has decreased 0.1% month over month and decreased 0.3% quarter over quarter
Epizyme's Trends
Twitter Engagement Stats for @EpizymeRx
628
Tweets
391
Following
2.9k
Followers
5
Tweets last 30 days
1.8
Avg. likes per Tweet
80%
Tweets with engagement
Epizyme News and Updates
August 09, 2021
HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China
Collaboration designed to accelerate global development and investigate TAZVERIK® combinations with HUTCHMED’s novel oncology medicines portfolio
May 07, 2021
Thinking about buying stock in Epizyme, AMC Entertainment, Evofem Biosciences, Nokia, or Arcutis Biotherapeutics?
NEW YORK, May 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EPZM, AMC, EVFM, NOK, and ARQT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
May 07, 2021
SVB Leerink upgrades Epizyme, citing sales potential for lymphoma drug
Shares of Epizyme Inc. were up 11.0% in premarket trading on Friday after SVB Leerink upgraded the company's stock to outperform, from market perform, citing Tazverik's potential opportunity in the follicular lymphoma market. Analyst Andrew Berens told investors that the drug's potential as a "main…
Epizyme Blogs
May 17, 2022
Epizyme To Participate in H.C. Wainwright Global Investment Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 17, 2022-- Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that Grant Bogle , President and Chief
May 10, 2022
Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update
TAZVERIK® (tazemetostat) Net Product Revenue of $ 8.7 Million for 1Q 2022, Supported by Streamlined Operating Expenses which Decreased by 17% in 1Q 2022 vs. 1Q 2021 First Patient Dosed in the Randomized Phase 3 Portion of SYMPHONY-1 (EZH-302), Epizyme’s Phase 1b/3 Confirmatory Study Assessing
May 03, 2022
Epizyme Announces Date of First Quarter 2022 Financial Results
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 3, 2022-- Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that management will host a conference
March 15, 2022
Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update
Appointment of Jerald Korn as Chief Operating Officer First Patient Dosed in the Randomized Portion of SYMPHONY-1 (EZH-302), Epizyme’s Phase 1b/3 Confirmatory Study of Tazemetostat in Combination with R 2 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 15, 2022-- Epizyme (Nasdaq: EPZM), a fully
March 02, 2022
Epizyme to Participate in Upcoming Healthcare Conferences in March
Epizyme to Participate in Upcoming Healthcare Conferences in March
Content Import
Wed, 03/02/2022 - 08:03
Epizyme to Participate in Upcoming Healthcare Conferences in March
Mar 02, 2022
This release is a backfill from a News Wire
General
…
March 01, 2022
Epizyme Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
TAZVERIK® (tazemetostat) Net Product Revenue of $11.6 Million for 4Q 2021; $30.9 Million for FY 2021 $85 Million in Gross Proceeds Raised in January 2022 Public Offering, Combined with Recent Expense Reductions Announced Today, Extends Cash Runway into 3Q 2023 Company Engaged in Global Start-up
Epizyme Frequently Asked Questions
When was Epizyme founded?
Epizyme was founded in 2007.
Who are Epizyme key executives?
Epizyme's key executives are David M Mott, Grant Bogle and Matthew Ros.
How many employees does Epizyme have?
Epizyme has 203 employees.
What is Epizyme revenue?
Latest Epizyme annual revenue is $15.8 m.
What is Epizyme revenue per employee?
Latest Epizyme revenue per employee is $77.6 k.
Who are Epizyme competitors?
Competitors of Epizyme include Imago BioSciences, Italfarmaco and Ascentage Pharma.
Where is Epizyme headquarters?
Epizyme headquarters is located at 400 Technology Square, 400 Technology Square, Cambridge.
Where are Epizyme offices?
Epizyme has an office in Cambridge.
How many offices does Epizyme have?
Epizyme has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies